You searched for: antiparkinsonian (Engelska - Slovenska)

dose adjustments of antiparkinsonian therapy
prilagajanje odmerka antiparkinsonikov

other antiparkinsonian medicinal products:
drugi antiparkinsoniki:

comtan has no antiparkinsonian activity without levodopa.
comtan brez levodope nima nikakršnega antiparkinsonskega učinka.

you may also use other antiparkinsonian medicines at the same time.
sočasno lahko jemljete tudi druga antiparkinsonska zdravila.

15 phosphokinase has been reported with the abrupt withdrawal of antiparkinsonian agents.
15 povišano telesno temperaturo, duševne spremembe in povišane vrednosti serumske kreatin fosfokinaze.

the dose of other antiparkinsonian medicines may need to be adjusted when you start taking comtan.
morda bo ob uvedbi zdravila comtan potrebno prilagoditi odmerke drugih zdravil za parkinsonovo bolezen.

abrupt discontinuation of both comtan and other antiparkinsonian medicines may result in unwanted side effects.
nenadna prekinitev zdravljenja s comtanom in drugimi antiparkinsonskimi zdravili lahko povzroči neželene učinke.

the doses of other antiparkinsonian medicinal products may need to be adjusted when entacapone treatment is initiated.
ob uvedbi zdravljenja z entakaponom je morda potrebno prilagoditi odmerke drugih antiparkinsonskih zdravil.

in such case, your doctor may need to re- adjust the dosage of your other antiparkinsonian medicines.
v takem primeru vam bo zdravnik mogoče prilagodil odmerjanje vaših drugih antiparkinsonskih zdravil.

to date there has been no indication of interactions that would preclude concurrent use of standard antiparkinsonian medicinal products with stalevo therapy.
do sedaj niso znane nobene interakcije, ki bi omejevale sočasno uporabo standardnih antiparkinsonikov in zdravila stalevo.

the doses of other antiparkinsonian medicinal products may need to be adjusted when stalevo treatment is substituted for a patient currently not treated with entacapone.
kadar zdravilo stalevo nadomešča terapijo pri bolniku, ki trenutno ne prejema entakapona, bo odmerke drugih antiparkinsonskih zdravil morda treba ustrezno prilagoditi.

particularly d2 receptor antagonists should be carried out with caution, and the patient carefully observed for loss of antiparkinsonian effect or worsening of parkinsonian symptoms.
antagonisti receptorjev d2, zahteva previdnost, bolnika pa je treba skrbno spremljati, če bi prišlo do izgube antiparkinsonskega učinka ali poslabšanja parkinsonskih simptomov.

if you suddenly stop taking levodopa/carbidopa/entacapone orion and other antiparkinsonian medicines it may result in unwanted side effects.
Če boste nenadno prenehali jemati tablete zdravila levodopa/carbidopa/entacapone orion in druge antiparkinsonike, lahko doživite neželene učinke.

if ongentys is discontinued it is necessary to adjust the dosing of the other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the symptoms.
pri prekinitvi zdravljenja z zdravilom ongentys je treba prilagoditi odmerek drugih antiparkinsonikov, zlasti levodope, da se doseže zadostna raven nadzorovanja simptomov.

a syndrome resembling the neuroleptic malignant syndrome including muscular rigidity, elevated body temperature, mental changes and increased serum creatine phosphokinase has been reported with the abrupt withdrawal of antiparkinsonian agents.
ob nenadni ukinitvi antiparkinsonikov poročajo o pojavu sindroma podobnega malignemu nevroleptičnemu sindromu, ki vključuje otrplost mišic, povišano telesno temperaturo, duševne spremembe in povišane vrednosti serumske kreatin fosfokinaze.

if entacapone treatment is discontinued, it is necessary to adjust the dosing of other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the parkinsonian symptoms.
v primeru prekinitve zdravljenja z entakaponom je treba za doseganje zadostne ravni nadzora nad parkinsonskimi simptomi prilagoditi odmerjanje drugih antiparkinsonskih zdravil, zlasti levodope.

concomitant administration of antipsychotics with dopamine receptor-blocking properties, particularly d2 receptor antagonists should be carried out with caution, and the patient carefully observed for loss of antiparkinsonian effect or worsening of parkinsonian symptoms.
sočasno dajanje antipsihotikov, ki delujejo kot zaviralci dopaminskih receptorjev, zlasti pa antagonistov receptorjev d2, zahteva previdnost, bolnika pa je treba skrbno spremljati, če bi prišlo do izgube antiparkinsonskega učinka ali poslabšanja parkinsonskih simptomov.

other antiparkinsonian medicinal products: to date there has been no indication of interactions that would preclude concurrent use of standard antiparkinsonian medicinal products with levodopa/carbidopa/entacapone orion therapy.
drugi antiparkinsoniki: do sedaj niso znane nobene interakcije, ki bi omejevale sočasno uporabo standardnih antiparkinsonikov in zdravila levodopa/carbidopa/entacapone orion.

discontinuation of corbilta therapy: if corbilta treatment (levodopa/carbidopa/entacapone) is discontinued and the patient is transferred to levodopa/ddc inhibitor therapy without entacapone, it is necessary to adjust the dosing of other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the parkinsonian symptoms.
prekinitev zdravljenja z zdravilom corbilta: Če je zdravljenje z zdravilom corbilta (levodopa/karbidopa/entakapon) prekinjeno, bolnik pa namesto tega začne prejemati terapijo z levodopo/zaviralci ddk brez entakapona, je treba za dosego zadovoljive ravni obvladovanja parkinsonskih simptomov prilagoditi odmerjanje drugih antiparkinsonikov, zlasti levodope.